Medical Affairs, BIOCON, Bengaluru
Title: METFORMIN IN EXTENDE D RELEASE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: RETROSPECTIVE STUDY IN SOUTH INDIA
Mr.Pradeep B. K is working under Medical Affairs at BIOCON, Bengaluru, INDIA.
Diabetes mellitus is a chronic and progressive condition among thhe most common metabolic diseases in genneral medical practice. Intensive lifestyle intervention and metformin can prevent or delay progreession to diabetes. Over the past decade, lifestyle interventions have been translated across various settings, but little is known about the translation of evidennce surrounding metformin use. The purpose of this study is to evaluate the effect of metformin exxtended release formulation on the glyce mic control gastrointestinal tolerability and patient satisfactioon. Design: Retrospective analysis over a 1-year period. We examinned data from August 2016 to July 2017 from ESIC hospital Peenya, Bangaluru using a retrospective analysis of metformin prescription amon g adults. Data were analyzed in 80 patients with type 2 diabetes not well controlled by diet (glycated hemoglobin [HbA1c] .7.0% and 8.5%). Patients were given metformin XR (Metadoze IPR® BIOCON) for a period of 4 months at the maximum tolerated dose. We evaluated, HbA1c, fasting, postprandial glucose and body weight. Moreover, at the baseline and after 4 months, we also validated the patients by SF 16 questionnaire to assess patients’ satisfaction toward treatments. After 4 mo nths, metformin XR gave a greater improvement in glycemic control. A reduction in total cholessterol (TC) and low-density lipoprotein (LDL) cholesterol was observed with metformin XR. Conclusion: Metformin XR formulation seems to be more effective in improving glyco-metabolic control, lipid profile in patients with type 2 diabetes mellitus. Fewer gastrointestinal side effects and a greater sense of well being and satisfaction were seen with this meedication.